Literature DB >> 8028378

Mitral valve replacement with maintenance of mitral annulopapillary muscle continuity in patients with mitral stenosis.

Y Okita1, S Miki, Y Ueda, T Tahata, T Sakai, K Matsuyama.   

Abstract

Postoperative left ventricular performance was evaluated in patients with mitral stenosis who underwent mitral valve replacement with maintenance of the continuity of the mitral anulus and papillary muscles. Mitral valve replacement with preservation of autologous chordae tendineae (n = 7) or their replacement with expanded polytetrafluoroethylene sutures (n = 14) was performed in 21 patients with mitral stenosis. Hemodynamic parameters were compared with those of 28 patients who underwent conventional mitral valve replacement and 27 patients who underwent open mitral valve commissurotomy. No deaths occurred in the early or late follow-up period. All hemodynamic parameters were improved after the operation, and no significant differences were detected among the three groups with regard to postoperative cardiac index or mitral valve area. No significant differences were observed in left ventricular end-diastolic volume index, end-systolic volume index, or contractility index, but the postoperative left ventricular ejection fraction in the chordal preservation and open commissurotomy groups was greater than that in the group having conventional mitral valve replacement. Postoperative regional shortening was greatest at the diaphragmatic portion in the chordal preservation group and at the long axis in the open commissurotomy group. In the mid-term postoperative period, although no differences were noted among the three groups in echocardiographic data or global ejection fraction measured by multigated equilibrium radionuclide angiography, the regional shortening at the anterolateral portion of the left ventricle in the chordal preservation and commissurotomy groups was greater than that in the group having conventional mitral valve replacement. Postoperative radionuclide angiography during exercise failed to demonstrate any difference between the ejection fraction in the chordal preservation group and that in the group having conventional mitral valve replacement.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8028378

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  Early bioprosthetic valve failure caused by preserved native mitral valve leaflets.

Authors:  Koji Takeda; Richard Lee
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-23

Review 2.  Management decisions in valvular heart disease: the role of radionuclide-based assessment of ventricular function and performance.

Authors:  J S Borer; D Wencker; C Hochreiter
Journal:  J Nucl Cardiol       Date:  1996 Jan-Feb       Impact factor: 5.952

3.  Long-term outcomes of mitral valve annuloplasty versus subvalvular sparing replacement for severe ischemic mitral regurgitation.

Authors:  Baotong Li; Hengchao Wu; Hansong Sun; Jianping Xu; Yunhu Song; Wei Wang; Shuiyun Wang
Journal:  Cardiol J       Date:  2018-03-23       Impact factor: 2.737

4.  Mitral valve replacement versus annuloplasty for treating severe functional mitral regurgitation.

Authors:  Kazunori Yoshida; Kenji Okada; Shunsuke Miyahara; Atsushi Omura; Takeshi Inoue; Hitoshi Minami; Yutaka Okita
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-09-05

5.  A remnant mitral subvalvular apparatus mimicking aortic valve vegetation after mitral valve replacement.

Authors:  Hyun-Jin Kim; Kyung-Hee Kim; Jae-Sung Choi; Jun-Sung Kim; Myung-A Kim; Joo-Hee Zo
Journal:  J Cardiovasc Ultrasound       Date:  2012-03-27

Review 6.  Beginning and development of surgery for acquired valvular heart disease in Japan.

Authors:  Kazuhiro Hashimoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-11-12

7.  Acute thrombosis of bioprosthetic mitral valve.

Authors:  Jin-Tae Kwon; Tae-Eun Jung; Dong-Hyup Lee
Journal:  J Cardiothorac Surg       Date:  2013-08-27       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.